Reports of hypersensitivity reactions (HSRs) to MTX are limited to single case studies. We retrospectively reviewed HSRs to MTX during a 12-year period in our tertiary care pediatric center. Seven patients were evaluated for HSRs to MTX. Skin testing was positive in one of the four patients tested. One patient underwent successful graded challenge to MTX. Seventeen desensitizations to MTX were successfully performed in the other six patients. Skin testing, graded challenge, and desensitization were safe and effective procedures in the evaluation and management of patients with HSRs to MTX in our pediatric population.
INTRODUCTION
Methotrexate (MTX) is a folate antimetabolite used to treat various malignancies and autoimmune conditions. 1 Hypersensitivity reactions (HSRs) to MTX are rare and usually occur with reexposure. 2 HSRs may include urticaria, angioedema, rash, abdominal pain, bronchospasm, dyspnea, and hypotension, and severe reactions are reported in <1% of HSR to MTX. 1 The mechanism of most immediate HSRs to MTX is suspected to be IgE-mediated, though other mechanisms may also be involved. 1 Skin testing and/or graded challenge are diagnostic procedures that may help in characterizing these reactions.
Skin testing can help in the initial diagnosis. In cases with negative skin testing and/or mild reactions, graded challenge may be considered. Graded challenge is a diagnostic procedure in which incremental doses of a drug are administered in a monitored setting while the patient is being observed; doses are not aimed at inducing tolerance. 3 In cases with positive skin testing and/or history of more significant reaction, desensitization should be considered, particularly when alternate therapies are not available and/or the drug to which the patient has reacted is the first-line therapeutic agent. Desensitization is the process of inducing temporary immunologic tolerance by administering gradually higher doses of a drug until the final cumulative therapeutic dose is achieved. Reports of MTX HSRs and desensitization in the adult and pediatric populations are limited to Abbreviations: HSR, hypersensitivity reaction; MTX, methotrexate case studies. [4] [5] [6] [7] [8] [9] [10] We discuss our experience in a pediatric population with HSRs to MTX including skin testing, graded challenge, and desensitization protocols. To our knowledge, this is the first case series describing the evaluation and management of HSRs to MTX, and the first report of using a 12-step desensitization protocol for MTX.
METHODS
We performed a retrospective chart review of patients undergoing graded challenge and desensitization to MTX at Boston Children's Hospital between 2002 and 2015. Institutional Review Board approval was obtained.
Skin testing
Skin testing was performed through our clinic's standard technique, at least 2-4 weeks after the initial reaction to reduce the possibility of false-negative results. 11 Skin prick testing to MTX was done at the concentration of 10 mg/ml; intradermal testing was done with 0.1, 1, and 10 mg/ml concentrations that were based on previous reports. 11, 12 Histamine (10 mg/ml) and saline were used as positive and negative controls, respectively. In three patients, skin testing was not performed due to the urgent need for drug administration. Based on skin testing results and clinical history, decision was made to perform either graded challenge or desensitization. 
Graded challenge and desensitization: Procedures and protocols
Before considering graded challenge or desensitization, we utilized the Brown Classification Criteria to characterize reaction severity (Table 1) . 13 The results of skin testing when performed also helped to determine the choice of procedure. Informed consent was obtained before the procedures that were performed with one-to-one nursing in an intermediate care or intensive care unit setting. Rescue medications (intravenous diphenhydramine, intramuscular epinephrine, nebulized albuterol, methylprednisolone, and normal saline) were available at the bedside.
Premedications were based on the well-described frequency of reactions during infusion and/or desensitization to chemotherapeutic agents. 14 Premedication regimens were aimed at minimizing breakthrough reactions during desensitization and were used in patients with more severe initial reactions. 14,15 Pretreatment regimens were selected based on the patient's history and/or the clinician's preference and were administered 1 hr prior to the start of the desensitization.
If breakthrough reactions occurred during desensitization, they were addressed by one or more of the following: stopping the infusion, treating the reaction, proceeding after lowering the infusion rate, and/or adding steps to the protocol. 11, 16 Most patients underwent desensitization using the protocol described in Table 2 . It is based on a 12-step desensitization protocol not previously reported for MTX desensitization, though successfully used for some other chemotherapeutic agents. 12 One patient who did not tolerate this 12-step protocol underwent a 16-step protocol that was previously described for other drugs but not MTX. 17 
RESULTS
Characteristics of the patients evaluated are shown in Table 1 . Seven patients were evaluated for HSR to high-dose MTX. Skin testing was performed in four of seven patients and not in the other three patients due to the urgency for readministration of MTX. Testing was positive in patient 5 only. Patient 3 had a history of a mild reaction to MTX including hives and pruritus, which occurred during concurrent administration of morphine. After negative skin testing, he tolerated a graded challenge to MTX without any reactions. 18 Future MTX infusions were tolerated without incident.
A total of 17 desensitizations to MTX were performed in patients 1-2 and 4-7. Two of the six patients received premedications before undergoing desensitization, which included one or more of the following: H1 antagonists, H2 antagonists, corticosteroids, and/or acetaminophen.
Most patients underwent desensitization using the protocol described in Table 2 . Patient 7 initially underwent 12-step desensitization. When the infusion rate was increased to 80 cc/hr, she developed hives, abdominal pain, and throat swelling. She received intravenous diphenhydramine and intravenous methylprednisone, and the rate of infusion was reduced to 60 cc/hr. For subsequent desensitizations, a 16-step protocol, previously described for other drugs but not MTX, 17 was 
DISCUSSION
To our knowledge, this is the first case series describing skin testing, graded challenge, and desensitization to MTX as well as the first report of using 12-step and 16-step desensitization protocols for this drug. In our experience, these procedures are safe and effective in the pediatric population.
In the setting of an immediate HSR to MTX, defining the nature of the HSR and skin testing in appropriate cases may guide the clinician in deciding to perform graded challenge or desensitization. Obtaining a tryptase level immediately following the reaction may be helpful in diagnosing IgE-mediated allergy. 11 If tryptase level is elevated and IgE-mediated reaction is suspected, desensitization may be favored over graded challenge. Tryptase levels were not obtained by the physicians taking care of our patients, possibly because these physicians are not specialized in allergy and hence are not familiar with the importance of sending this test. While MTX skin testing is reported, there is no extensive data on the validity of skin testing to MTX. In some cases when the use of chemotherapy is urgent, skin testing may not be feasible due to time constraints. In addition, if the patient's HSR occurred recently, the probability of false-negative reactions on skin testing is increased. 11 In those situations, desensitization may be the only option if treatment with the drug is deemed necessary. Also in patients with negative skin testing, who have a history of severe HSR to the drug, desensitization should still be favored over graded challenge. In patients with negative skin testing, based on the clinical history, graded challenge may be considered, as we did for patient 3 in our case series.
In patient 3, the clinical history along with negative skin testing led to the decision to perform graded challenge. However, in patients with negative skin testing, who have a history of severe HSR to the drug, desensitization may still be favored over graded challenge. Although such procedures are most effective in IgE-mediated reactions, desensitization is also used successfully in non-IgE-mediated HSRs. 16 While there are several case reports involving MTX desensitization in pediatric and adult patients, [5] [6] [7] [8] [9] these reports describe the use of prolonged infusions, ranging from 11 to 33 hr, rather than stepwise, twofold increase in dose-based 12-step and 16-step desensitization protocols that have also been successfully used for other chemotherapy agents. 17 This 12-step protocol has been adopted as a safe and cost-effective method of administering chemotherapy, and as the standard at our institution and others. 12, 14 All of our patients tolerated the desensitization procedures well and were able to receive the benefits of treatment.
In patients with HSRs to MTX, graded challenge or desensitization to this drug may be considered based on the history, skin testing, and availability of alternate therapies. In our experience, these procedures 
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